11 Nov 2025
9m
The early part of 2026 is going to be a key time for REGENXBIO's gene therapies, with an FDA decision date schedule for Hunter's Syndrome and a pivotal trial readout in DMD
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.